Obesity Pill Revolution: Daily Tablet Challenges Weight Loss Injections
A new daily pill to treat obesity has just been approved in the United States, and its makers suggest Britain could soon follow suit. This development signals a rapid transformation in the health landscape, potentially revolutionising weight loss approaches. The approval of Foundavo (orforglipron) by the U.S. Food and Drug Administration on April 1 offers an alternative to the weekly self-administered injectable GLP-1 drugs that have dominated the market.
The Rise of the Ozempic Era and Its Evolution
Just over two years ago, Ozempic emerged as a so-called "miracle" medication, quickly revolutionising the weight loss industry. It became a coveted accessory in Hollywood, a status symbol, and a go-to injectable for dramatic transformations. The Ozempic era has been marked by cycles of skepticism, celebrity denials and admissions, side-effect concerns like nausea and vomiting, and notorious "boomerang" weight gain after treatment ends.
Despite these issues, demand for GLP-1 receptor agonists like Wegovy and Mounjaro remains insatiable, leading to global shortages that affect type 2 diabetes patients who rely on them. Prescriber crackdowns on BMI falsifications have begun, and prices in the UK are approaching £300 per month. In a significant step, the Medicines and Healthcare products Regulatory Agency approved semaglutide in July 2024 for reducing cardiovascular risk in overweight adults with heart disease, expanding its role beyond weight management.
The New Frontier: Oral Weight Loss Pills
Foundavo, developed by Eli Lilly, is the second daily obesity pill approved by the FDA, joining Novo Nordisk's Wegovy pill approved in December 2025. Orforglipron, its generic name, is still awaiting approval in the UK, where trials are ongoing, but it is expected to be released later this year. Recent clinical trials show the drug helps patients shed an average of 12.4% of their body weight, a significant achievement, though less than the most powerful injections.
Patrik Jonsson, Eli Lilly's European president, has spoken about pursuing a "once-and-done" treatment for obesity, calling it a huge contribution to humanity, though such a breakthrough remains years away. Like injectables, orforglipron targets GLP-1 receptors to suppress appetite and slow digestion, but it offers advantages: no refrigeration is required, it can be taken at any time with or without food, and it is expected to be cheaper to manufacture and distribute.
Market Expansion and Alternative Solutions
As the oral pill revolution advances, a new market for "natural" alternatives is rapidly expanding. Wellness brands are offering supplements or patches that claim to increase hunger-regulating hormones without injectables. Examples include Kind Patches' "GLP-1 Patches" and Kourtney Kardashian Barker's Lemme brand products. Halle Berry has joined biotech company Pendulum Therapeutics, which sells a GLP-1 boosting probiotic.
Another startup, Metabolize, is taking a different approach with a metabolite-driven oral supplement that mimics the benefits of the keto diet. Based on animal studies, it claims to provide 10-20% weight loss with regular use. Dr. Morris Laster, the founder, explains that their product targets brain-based neural pathways for appetite regulation, aiming to be safe, cheap, and side-effect free. He notes that over 80% of people on GLP-1 drugs stop within a year due to side effects like nausea and potential thyroid cancer risks.
Future Implications and Healthcare Challenges
The race for alternatives is driven by high demand; an estimated 3.4 million Brits meet criteria for Wegovy or Mounjaro prescriptions, which could cost the NHS £10 billion annually, potentially straining its resources. Novo Nordisk anticipates future developments will narrow the gap between medical and surgical weight loss options. Research into targeting entero-pancreatic hormones released during eating shows promise for monumental healthcare impacts.
This evolving market highlights a weight loss revolution that is only just beginning, with oral pills like Foundavo poised to change how millions manage obesity, offering a simpler, more accessible option compared to weekly injections.
